Back to top
more

ACADIA Pharmaceuticals (ACAD)

(Real Time Quote from BATS)

$18.53 USD

18.53
468,125

+0.87 (4.93%)

Updated Nov 11, 2024 12:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Acadia's Q3 Earnings Beat, Nuplazid & Daybue Drive Revenue Growth

by Zacks Equity Research

ACAD reports encouraging third-quarter results as earnings and revenues beat estimates. Nuplazid and Daybue sales record year-over-year growth.

Acadia Pharmaceuticals (ACAD) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Acadia (ACAD) delivered earnings and revenue surprises of 53.85% and 0.46%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy, Sell or Hold DENTSPLY SIRONA Before Q3 Earnings?

by Zacks Equity Research

XRAY's third-quarter results are likely to reflect growth in the Wellspect Healthcare business and Orthodontic segment amid foreign exchange headwinds.

Should You Buy, Sell or Hold McKesson Before Q2 Earnings?

by Zacks Equity Research

MCK's second-quarter fiscal 2025 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment, driven by higher prescription volume.

Cencora to Report Q4 Earnings: What's in Store for the Stock?

by Zacks Equity Research

COR's fiscal fourth-quarter results are likely to reflect decent U.S. Healthcare Solutions segmental performance.

Arcturus Gears Up to Report Q3 Earnings: Here's What to Expect

by Zacks Equity Research

On ARCT's third-quarter 2024 earnings call, investors' focus is likely to be on the upcoming launch of its COVID-19 vaccine, Kostaive and other pipeline updates.

Revvity to Report Q3 Earnings: What's in Store for the Stock?

by Zacks Equity Research

RVTY third-quarter results are likely to reflect decent performance in the Diagnostics segment, while the Life Sciences segment is likely to face continued challenges in China.

Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Lower Volume Likely to Hurt GE HealthCare's Q3 Earnings

by Zacks Equity Research

GEHC's third-quarter results are likely to witness declining segmental revenues in imaging, ultrasound and patient care. The bottom-line figure may reflect better pricing.

Lower Instruments Sales to Hurt TXG Q3 Earnings, Prelim Sales Down

by Zacks Equity Research

Per a preliminary report from 10x Genomics, the company's revenues will decline for the third quarter. Lower Instruments sales are likely to have been partially offset by consumable sales growth.

Strong Segmental Performance to Drive Stryker's Q3 Earnings

by Zacks Equity Research

SYK's third-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.

Ecolab's Set to Report Q3 Earnings: What's in Store for the Stock?

by Zacks Equity Research

ECL third-quarter results are likely to reflect continued segmental strength.

Cardinal Health to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Despite recent supply chain challenges, new facilities and the acquisition of Specialty Networks are likely to have driven CAH's growth

Do Options Traders Know Something About Acadia (ACAD) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Acadia (ACAD) stock based on the movements in the options market lately.

Will CGM Sensor Demand Continue to Drive DexCom Q3 Earnings?

by Zacks Equity Research

DXCM's third-quarter 2024 results are likely to reflect rising volumes across all channels.

What's in Store for West Pharmaceutical in Q3 Earnings?

by Zacks Equity Research

WST's third-quarter 2024 results are likely to reflect weakness in its Proprietary Products business. Unfavorable currency movements might have hurt the top and bottom lines.

Will FARAPULSE Line Aid Boston Scientific's Q3 Earnings?

by Zacks Equity Research

BSX is expected to have registered strong growth in the Asia Pacific, which is led by strength in China and Japan.

Why Acadia (ACAD) Could Beat Earnings Estimates Again

by Zacks Equity Research

Acadia (ACAD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Edwards Lifesciences to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

EW is likely to have witnessed continued growth in TAVR procedures across the United States and worldwide in the third quarter.

Abbott's Q3 Earnings Release Coming Up, EPD Business in Focus

by Zacks Equity Research

ABT's Neuromodulation growth is expected to have been driven by strong demand in international markets for the Eterna rechargeable spinal cord stimulation device.

DGX Gears Up for Q3 Earnings: What Lies Ahead for the Stock?

by Zacks Equity Research

Quest Diagnostics is expected to deliver robust base business growth in the third quarter of 2024.

Labcorp's Q3 Earnings Looms: Here's What to Expect From the Stock

by Zacks Equity Research

LH is expected to perform strongly in both of its segments and will also likely advance in its strategic priorities.

Robust Analytical Instrument Segment Likely to Aid TMO's Q3 Earnings

by Zacks Equity Research

Strength in Analytical Instrument and Specialty Diagnostics segments is likely to have driven Thermo Fisher's third-quarter 2024 performance.

Will Auvelity & Sunosi Fuel Axsome's Growth Amid Stiff Competition?

by Zacks Equity Research

AXSM's depression drug, Auvelity, is driving the top line while Sunosi diversifies its business. Stiff competition in the target market remains a concern.

ACAD or TECH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ACAD vs. TECH: Which Stock Is the Better Value Option?